Asset profile

povorcitinib · Incyte (INCY)

Indication: hidradenitis suppurativa (HS)
Also known as: Povofortay

Company

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthr…

Start live analysis of INCY Run 8-agent AI analysis

On the calendar

Oct 2026

Oct 19, 2026

12 days ago

INCYIncyte

povorcitinib: Phase 3 trial NCT06516952 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionOutcome not recordedClinicalTrials.gov

Oct 2026

Oct 19, 2026

12 days ago

INCYIncyte

povorcitinib: Phase 3 trial NCT06516965 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionOutcome not recordedClinicalTrials.gov

Nov 2026

Nov 20, 2026

in 20 days

INCYIncyte

povorcitinib: Phase 2 trial NCT05851443 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.gov

Dec 2026

Dec 26, 2026

in 56 days

INCYIncyte

povorcitinib: Phase 3 trial NCT06212999 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.gov

Feb 2028

Feb 28, 2028

in 485 days

INCYIncyte

povorcitinib: Phase 3 trial NCT06855498 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.gov

Mar 2028

Mar 25, 2028

in 511 days

INCYIncyte

povorcitinib: Phase 2 trial NCT07213973 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.gov

May 2028

~ May 2028

INCYIncyte

povorcitinib: Phase 3 trial NCT07865312 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.govMonth only

Timeline

Newest first.

Oct 30, 2026

03:22 PM

INCYIncyte

povorcitinib · NCT06855498 registry update

Trial registry changeClinicalTrials.gov

Oct 29, 2026

11:03 AM

INCYIncyte

Incyte povorcitinib NDA under review for HS; potential US approval Q1 2027

OtherSEC 8-K

Oct 9, 2026

03:22 PM

INCYIncyte

povorcitinib · NCT06855498 registry update

Trial registry changeClinicalTrials.gov

Sep 16, 2026

03:21 AM

INCYIncyte

povorcitinib · NCT06855498 registry update

Trial registry changeClinicalTrials.gov

Apr 28, 2026

11:03 AM

INCYIncyte

Incyte: FDA accepts NDA for povorcitinib in hidradenitis suppurativa

Application acceptedSEC 8-K Open record

Registered trials

Registry ID	Phase	Status	Primary completion	Enrollment	Sites
NCT06855498	Phase 3	Recruiting	Feb 28, 2028	600	94 of 306 sites in the United States
NCT05620836	Phase 3	Completed	Jan 7, 2025	619	38 of 101 sites in the United States
NCT05620823	Phase 3	Completed	Feb 3, 2025	608	37 of 104 sites in the United States
NCT06113445	Phase 3	Active, not recruiting	Feb 24, 2026	467	34 of 100 sites in the United States
NCT05936567	Phase 2	Completed	Feb 28, 2025	136	22 of 42 sites in the United States
NCT07213973	Phase 2	Recruiting	Mar 25, 2028	40	26 of 30 sites in the United States
NCT06516952	Phase 3	Active, not recruiting	Oct 19, 2026	349	31 of 120 sites in the United States
NCT05851443	Phase 2	Active, not recruiting	Nov 20, 2026	247	26 of 82 sites in the United States
NCT06516965	Phase 3	Active, not recruiting	Oct 19, 2026	346	28 of 119 sites in the United States
NCT06212999	Phase 3	Active, not recruiting	Dec 26, 2026	617	61 of 165 sites in the United States
NCT06113471	Phase 3	Active, not recruiting	Mar 17, 2026	450	33 of 86 sites in the United States
NCT07865312	Phase 3	Not yet recruiting	May 1, 2028	174	0 of 44 sites in the United States

More from Incyte

Other drugs and candidates from the same company tracked in this sector.

baricitinibsevere alopecia areata INCB161734KRAS G12D-mutated pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC)petosemtamabfirst-line PD-L1 positive recurrent/metastatic head and neck squamous cell carcinoma (HNSCC)PRT12396polycythemia vera and myelofibrosis retifanlimab-dlwrmetastatic non-small cell lung cancer (NSCLC) in combination with platinum-based chemotherapy ruxolitinibatopic dermatitis tafasitamabfirst-line diffuse large B-cell lymphoma (DLBCL)zilurgisertibfibrodysplasia ossificans progressiva (FOP)